To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Biomarkers Consortium - Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer's Disease

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium’s Plasma Abeta project will evaluate next generation plasma Aβ assays to determine whether plasma Aβ peptide ratios increase the probability of identifying patients with amyloid positivity to improve clinical trial screening efficiency and reduce clinical trial costs for early stages of Alzheimer’s Disease.

2019 Alzheimer's Disease-Related Dementia (ADRD) Summit

The National Institutes of Health (NIH) is convening the 3rd Alzheimer's Disease-Related Dementia Summit, to be held on March 14-15, 2019 in Bethesda, Maryland. The 2019 Summit will bring together leading researchers, innovators and public advocates from academia, industry, the non-profit sector and NIH to discuss progress made on dementia related research and develop recommendations that will help facilitate new scientific discoveries.

2018 Alzheimer’s Disease Research Summit

National Institutes of Health convened the 3rd Alzheimer’s Disease (AD) Research Summit on March 1-2, 2018 in Bethesda, Maryland. The program built on the foundation laid by the 2012 and 2015 NIH AD Research Summits and the U.S. National Alzheimer’s Project Act (NAPA)/National Plan to Address AD.

National Research Summit on Dementia Care: Building Evidence for Services and Supports

On October 16-17, 2017, the National Advisory Council on Alzheimer’s Research, Care and Services held a two-day Summit on the NIH campus entitled: National Research Summit on Dementia Care: Building Evidence for Services and Supports. The purpose of the Summit was to address the growing need for evidence that improves the quality of care and support provided to persons with dementia and their caregivers.

Cognitive Aging Summit III

Cognitive Aging Summit III will bring together experts in a variety of research fields to discuss the most cutting edge advances in our understanding of age-related brain and cognitive changes, with a particular focus on resilience and reserve.

2016 Alzheimer's Disease-Related Dementias (ADRD) Summit

The 2016 Alzheimer’s Disease-Related Dementias (ADRD) Summit was hosted by the National Institute of Neurological Disorders and Stroke (NINDS) in collaboration with the National Institute on Aging (NIA) and held March 29-30, 2016 at the Natcher Auditorium on the NIH Campus.

Alzheimer's Disease Neuroimaging Initiative 2

ADNI was established to facilitate the development of effective treatments for Alzheimer’s disease by validating biomarkers for clinical trials and determining the relationships between the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics of AD.  

Biomarkers Consortium - Use of Targeted Multiplex Proteomic Strategies to Identify CSF-Based Biomarkers in Alzheimer’s Disease

The AD Targeted Cerebrospinal Fluid (CSF) Proteomics Project, completed in Q2Y15, completed an initial validation of a multiplexed panel of known biomarkers, examined BACE levels and enzymatic activity, and set up the initial validation of a mass spectroscopy panel using AD cerebrospinal fluid samples from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Biomarkers Consortium - Comparison of Two PET Radioligands to Quantify the Peripheral Benzodiazepine Receptor

The Biomarkers Consortium’s PET Radioligand Project, completed in December 2012, developed improved, more sensitive PET radioligands with higher binding to the peripheral benzodiazepine receptor. Findings from this study suggest that the [11C]PBR38 ligand, in particular, may be useful in detecting progression from mild cognitive impairment or treatment response in Alzheimer’s Disease.

Biomarkers Consortium - Diabetes Drug Development: Identification and Validation of Markers That Predict Long-Term Beta Cell Function and Mass

This is the first project in a two-stage strategy that seeks to characterize beta cell function for predicting long-term beta cell response to an intervention based on short-term measures. The first stage’s goal is to characterize key methodological issues in the assessment of beta cell function by evaluating Mixed Meal Tolerance (MTT) and Arginine Stimulation Tests against the standard Frequently Sampled Intravenous Glucose Tolerance (FSIGT) Test in a series of clinical studies.